2
23andMe
Helping people access, understand, and benefit from the human genome
At a glance
- Status
- Listed
- Listing
- Public via SPAC 2021
Knowledge graph
Market map
Rare Disease Therapeutics & Technologies Landscape
Market map
1k+ Global Genetics & Genomics startups
Unicorn list
Biotech & Life Sciences unicorns
Unicorn list
Unicorns in United States
Open roles
23andMe in the Sunnyvale ecosystem
The 23andMe office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
- GEGenentech
- MVMohr Davidow Ventures
- SMStephens Investment Management
Alphabet | Google
NEA
Series B and later13 investors entered at this stage
- JCJohnson & Johnson Development Corporation
- GSGSK
Fidelity Investments
Sequoia- NCNewView Capital
Illumina- SBSergey Brin
Casdin Capital- YMYuri Milner
- XFXfund
- AWAnne Wojcicki
- MBMPM BioImpact
- FCFuture Planet Capital
Source: Dealroom Talent Intelligence.
Alumni founders
Former 23andMe employees who went on to found companies, sorted by Dealroom signal score.
BIBioptimusEst. 2023
Eric DurandFrance
LELevelsEst. 2019
Casey MeansUnited States
BHBrightside HealthEst. 2017
Brad KittredgeUnited States
Pierre-Eric LeiboviciFrance
MAMainStreetEst. 2019Patents
50 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where 23andMe was the backer or acquirer, 2012–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
4 deals across 23andMe's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Where 23andMe deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
23andMe's portfolio, mapped.
See 23andMe on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
23andMe Research Institute closes $305M buy of 23andMe assets after Regeneron $256M bid (July 2025)
Mapmygenome buys Canada's dnaPower to build out North American testing platform